Quarterly report pursuant to Section 13 or 15(d)

4. Significant Strategic Drug Development Collaborations

v2.4.1.9
4. Significant Strategic Drug Development Collaborations
3 Months Ended
Mar. 31, 2015
Research and Development [Abstract]  
Significant Strategic Drug Development Collaborations

The Company has entered into various research, development, license and supply agreements with Baxter Healthcare SA (“Baxter SA”) and Baxter Healthcare Corporation (together referred to as “Baxter”), SynBio LLC (“SynBio”), Serum Institute of India (“Serum Institute”) and OJSC Pharmsynthez (“Pharmsynthez”). The Company and its collaborative partners continue to engage in research and development activities with no resultant commercial products through March 31, 2015. No amounts were recognized as revenue related to these agreements during the three months ended March 31, 2015 or 2014.